AZ, Bristol unveil Forxiga in U.K.; Study: Warfarin may be riskier than previously thought;

@FiercePharma: Merck KGaA says it won't offload its consumer health unit, despite promise of big $$. Report | Follow @FiercePharma

> AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) launched their new diabetes drug Forxiga in the U.K. after its European approval earlier this month. Report

> Seattle Genetics ($SGEN) said its cancer treatment Adcetris won orphan drug status for treating mycosis fungoides, the most common type of cutaneous T-cell lymphoma; it's already approved for two other types of lymphoma. Report

> The common blood thinner warfarin is associated with more serious bleeding events in real-world use than in clinical trials, a study found, but the study author cautioned against interpreting the results as an endorsement of newer warfarin alternative drugs. Report

> South Africa's Cipla Medpro said its CFO resigned, soon after CEO Jerome Smith quit amid allegations of financial irregularities. Report

> Despite opposition to vague language in the Massachusetts legislature's provision relaxing the pharma gift ban, the state's Public Health Council implemented it mostly as-is. Report

> Lundbeck hired Ogilvy PR Health to help launch its new antidepressant vortioxetine, which is awaiting approval from European and U.S. regulators. Report

> The British pharma association is once again urging the country's National Health Service to quickly adopt new drugs recommended by the cost-effectiveness watchdog NICE. Report

Biotech News

 @FierceBiotech: In case you missed it: Top 50 Industry Voices in Biotech Twittersphere -- 2012. Special Report | Follow @FierceBiotech

 @JohnCFierce: Updated Acadia story with CEO comments on pimavanserin dev plans. Confirm Ph3, pursue schizophrenia and Alzheimer's psychosis. Story | Follow @JohnCFierce

 @RyanMFierce: Why Big Data alone lacks the punch pharma needs. Article | Follow @RyanMFierce

> China fosters biosimilar drug R&D with new set of custom guidelines. More

> Pfizer gets Rhythm with $8M bet on diabetes, obesity drug work. News

Medical Device News

 @FierceMedDev: New special report: Top 10 Diagnostics Companies 2012. Report | Follow @FierceMedDev

@MarkHFierce: Venture funding lives: TriReme Medical pulled in $18 million in a new round. Release | Follow @MarkHFierce

 @DamianFierce: As Mindray Medical knows, being a Chinese company gives you cost advantages but can come with some PR hurdles. More | Follow @DamianFierce

> India's Trivitron expands Dx reach with $20.4M buy. Article

> Merit buys GE unit for $167M. News

Pharma Manufacturing News

> Some 'misbranded drugs' turned up in Avastin probe came from Roche plant. News

> Switzerland, home of Roche and Novartis, gets pass from EU API rule. Story

> EMA wants manufacturers to offer up drug shortage 'risk analysis'. Article

> Novartis gets FDA OK for faster flu vaccine production at U.S. plant. More

Biotech Research News

> German team combines 2 old drugs for new MS treatment. More

> Stem cell-reliant HIV vaccine launches animal studies in January. Article

> Anti-cancer virus could gain new power with patient immune cell tweak. Story

> McGill scientists link autistic behavior to brain protein mutation. Item

And Finally... Short bursts of exercise have an immediate effect on memory in healthy older adults--and in those with mild cognitive problems. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.